MedTrace Logo

Hesperidin RCT in MS

NCT07452562 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-05

No results posted yet for this study

Summary

This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.

Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.

Conditions

Interventions

DIETARY_SUPPLEMENT

Hesperidin

500 mg/day Hesperidin capsules for 12 weeks

DIETARY_SUPPLEMENT

Placebo

Matching maltodextrin capsules for 12 weeks.

Sponsors & Collaborators

  • BioActor B.V.

    collaborator INDUSTRY

  • Swansea University

    lead OTHER

Principal Investigators

  • Hayley A Young, PHD · Swansea University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-07
Primary Completion
2027-01-18
Completion
2027-01-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07452562 on ClinicalTrials.gov